Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China
用户5TLJU3iD5n3A
2个月前
52
10
已完结
1. 系统已在2025-07-30 10:04:49对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1186/s13561-025-00656-1
文献链接: https://healtheconomicsreview.biomedcentral.com/articles/10.1186/s13561-025-00656-1
其他信息:
出版社: Springer Science and Business Media LLC
作者: Luwei Wang; Jiasheng Chen; Lihui Lin; Xiaowei Huang
全文下载地址: https://link.springer.com/content/pdf/10.1186/s13561-025-00656-1.pdf
